Large clinical trials demonstrated that SGLT2 inhibitors (dapagliflozin, empagliflozin and canagliflozin) lead to improved cardiac and renal outcomes in patients with type 2 diabetes mellitus [5–9]. This evidence concerns the gene SLC5A2 and diabetes mellitus.